LncRNA ZFAS1 inhibits triple-negative breast cancer by targeting STAT3

被引:25
|
作者
Sharma, Uttam [1 ]
Barwal, Tushar Singh [1 ]
Khandelwal, Akanksha [2 ]
Malhotra, Akshay [3 ]
Rana, Manjit Kaur [4 ]
Rana, Amrit Pal Singh [5 ]
Imyanitov, Evgeny N. [6 ]
Vasquez, Karen M. [7 ]
Jain, Aklank [1 ]
机构
[1] Cent Univ Punjab, Dept Zool, City Campus,Mansa Rd, Bathinda 151001, Punjab, India
[2] Cent Univ Punjab, Dept Biochem, Bathinda 151001, India
[3] Otto von Guericke Univ, Inst Expt Internal Med, Magdeburg, Germany
[4] AIIMS, Dept Pathol Lab Med, Bathinda 151001, Punjab, India
[5] Baba Farid Univ Hlth Sci, Faridkot, Punjab, India
[6] NN Petrov Inst Oncol, St Petersburg, Russia
[7] Univ Texas Austin, Dell Paediat Res Inst, Coll Pharm, Div Pharmacol & Toxicol, 1400 Barbara Jordan Blvd, Austin, TX 78723 USA
关键词
Breast cancer; Long non-coding RNA; ZFAS1; Biomarker; TNBC; Triple-negative breast cancer;
D O I
10.1016/j.biochi.2020.12.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer (TNBC) isa highly aggressive subtype of breast cancer with fewer treatment options than other types of invasive breast cancer due to the loss of the estrogen, progesterone receptors and low levels of the HER2 protein, resulting in a poor prognosis for these patients. Here, we found that the expression of the lncRNA, ZFAS1, was significantly downregulated (-3.0-fold) in blood samples of TNBC patients (n=40) compared to matched healthy controls (n=40). Functionally, silencing of ZFAS1 promoted cell proliferation and colonization of human MDA-MB-231 TNBC cells by inhibiting the expression levels of the cyclin-dependent kinase (CDK) inhibitors p21 (CDKN1A) and p27 (CDKN1B) compared to the scrambled siRNA control cells. Further, we found that downregulation of ZFAS1 led to decreased protein levels of the epithelial markers, E-cadherin, Claudin-1, and Zo-1, with increased protein levels of the mesenchymal markers, Slug and ZEB1. In addition, by utilizing the bioinformatic tools such as RAID v2.0 (RNA Interactome Database Version 2.0), AnnoLnc (Annotate human lncRNA database), and GEPIA (Gene Expression Profiling Interactive Analysis), we identified a strong negative correlation between ZFAS1 and signal transducer and activator of transcription 3 (STAT3) gene expression (R =-0.11, p-value = 0.0002). Further, we observed that decreased ZFAS1 expression significantly (p < 0.05) increased STAT3 and phosphorylated STAT3 (at Ser727 residue) protein levels in TNBC cells. The composite data indicate that ZFAS1 may function as a tumor-suppressor lncRNA with potential as a diagnostic/prognostic marker and may offer a new target for the treatment of TNBC patients. (C) 2021 Elsevier B.V. and Societe Francaise de Biochimie et Biologie Moleculaire (SFBBM). All rights reserved.
引用
收藏
页码:99 / 107
页数:9
相关论文
共 50 条
  • [1] Treating estrogen receptor (ER)-negative and triple-negative breast cancer by targeting STAT3 signaling with putative STAT3 inhibitors.
    Kim, Hyejin
    Fricke, Doerte R.
    Xu, Jimin
    Chen, Haiying
    Zhou, Jia
    Shen, Qiang
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [2] Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy
    Feng, Tingting
    Cao, Wei
    Shen, Wanxiang
    Zhang, Liang
    Gu, Xinsheng
    Guo, Yang
    Tsai, Hsiang-i
    Liu, Xuewen
    Li, Jian
    Zhang, Jingxuan
    Li, Shan
    Wu, Fuyun
    Liu, Ying
    [J]. ONCOTARGET, 2017, 8 (01) : 329 - 344
  • [3] Osthole inhibits triple negative breast cancer cells by suppressing STAT3
    Dai, Xuanxuan
    Yin, Changtian
    Zhang, Yi
    Guo, Guilong
    Zhao, Chengguang
    Wang, Ouchen
    Xiang, Youqun
    Zhang, Xiaohua
    Liang, Guang
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [4] Osthole inhibits triple negative breast cancer cells by suppressing STAT3
    Xuanxuan Dai
    Changtian Yin
    Yi Zhang
    Guilong Guo
    Chengguang Zhao
    Ouchen Wang
    Youqun Xiang
    Xiaohua Zhang
    Guang Liang
    [J]. Journal of Experimental & Clinical Cancer Research, 37
  • [5] Flubendazole targets STAT3 signaling and distant metasis in triple-negative breast cancer
    Oh, Eunhye
    Kim, Yoon-Jae
    Jang, Seojin
    Cho, Tae-Min
    Park, Soeun
    Park, Jung Min
    Park, Minsu
    Kim, Ji Young
    Seo, Jae Hong
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [6] Eupalinolide J Suppresses the Growth of Triple-Negative Breast Cancer Cells via Targeting STAT3 Signaling Pathway
    Lou, Chenghua
    Chen, Yan
    Zhang, Jie
    Yang, Bo
    Zhao, Huajun
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [7] Targeting triple-negative breast cancer
    Kirkpatrick, Peter
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) : 21 - 21
  • [8] Targeting triple-negative breast cancer
    Peter Kirkpatrick
    [J]. Nature Reviews Drug Discovery, 2009, 8 : 21 - 21
  • [9] Targeting Triple-Negative Breast Cancer
    Saljoughian, Manouchehr
    [J]. US PHARMACIST, 2020, 45 (10) : 6 - 8
  • [10] MYCL promotes the progression of triple-negative breast cancer by activating the JAK/STAT3 pathway
    Jiang, Hongnan
    Li, Xiaojun
    Wang, Wei
    Hu, Yaofeng
    Ren, Dongliang
    [J]. ONCOLOGY REPORTS, 2022, 48 (05)